Treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men. Indicated for use in combination with prednisone or prednisolone for: Patients whose disease has progressed on or after a docetaxel-based chemotherapy regimen. Patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).

Dosage and administration

Daily Dose: 1,000 mg (4 tablets of 250 mg) taken once a day. ⚠️ IMPORTANT SAFETY RULE: 🚫 Take on an empty stomach. No food should be consumed for at least 2 hours before and 1 hour after the dose. Systemic exposure to abiraterone increases significantly when taken with food, increasing the risk of side effects. Swallow whole with water. Co-medication: Take with low-dose prednisone (usually 5 mg twice daily) to manage mineralocorticoid-related side effects.

Severe hepatic impairment (Child-Pugh Class C). Hypersensitivity to the active substance. Pregnancy or women who may become pregnant. Warning: This drug is not for use in women. Pregnant women should not handle the medication without gloves due to potential harm to the fetus.

Common adverse reactions (often managed by prednisone): Fluid retention (edema). Hypokalemia (low potassium). Hypertension. Fatigue and joint pain. Liver function tests (ALT/AST) and bilirubin should be monitored regularly.

Abirakast — Abiraterone Acetate 250 mg, 120 pcs, Aprazer

100% original product

Active ingredient

Abiraterone Acetate

Manufacturer

Aprazer

Dosage 250 mg

Dosage form Tablets

Tablets per pack 120

Abirakast (Abiraterone Acetate) 250 mg

Name: Abirakast
Brand: Aprazer
SKU: PROD-5
Price: 3955 UAH
Availability: InStock

3955₴ ~~4834₴~~ -18%

Abirakast is an effective anti-cancer medication used in the management of prostate cancer. Active ingredient: Abiraterone Acetate (250 mg).

Manufacturer: Aprazer Healthcare (India). A generic version of Zytiga. It works as a selective inhibitor of the enzyme CYP17, essential for androgen biosynthesis.

Benefits:

✅ Significantly extends survival rates in mCRPC patients.
✅ Delays the need for chemotherapy and reduces cancer-related pain.
✅ Must be co-administered with prednisone.

Treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men.

Indicated for use in combination with prednisone or prednisolone for:

Patients whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
Patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).

Daily Dose: 1,000 mg (4 tablets of 250 mg) taken once a day.

⚠️ IMPORTANT SAFETY RULE:

🚫 Take on an empty stomach. No food should be consumed for at least 2 hours before and 1 hour after the dose.
Systemic exposure to abiraterone increases significantly when taken with food, increasing the risk of side effects.
Swallow whole with water.

Co-medication: Take with low-dose prednisone (usually 5 mg twice daily) to manage mineralocorticoid-related side effects.

Severe hepatic impairment (Child-Pugh Class C).
Hypersensitivity to the active substance.
Pregnancy or women who may become pregnant.

Warning: This drug is not for use in women. Pregnant women should not handle the medication without gloves due to potential harm to the fetus.

Common adverse reactions (often managed by prednisone):

Fluid retention (edema).
Hypokalemia (low potassium).
Hypertension.
Fatigue and joint pain.

Liver function tests (ALT/AST) and bilirubin should be monitored regularly.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 09.03.2026